

Ref. No.: NLL/CS/2025- 539

August 14, 2025

To,
National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051
Symbol: NECLIFE

BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001
Scrip Code: 532649

Sub: Outcome of Board Meeting

Ref.: Regulation 30 and 33 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulation").

Dear Sir/ Madam,

We wish to inform you that the board of directors of Nectar Lifesciences Limited ("Company") in their meeting held on August 14, 2025, have, inter-alia, noted, decided and approved the following matters:

1. The unaudited standalone and consolidated financial results for the quarter ended on June 30, 2025, which are enclosed herewith along with the limited review reports of the auditors thereon as **Annexure- A**;
2. To convene the 30th annual general meeting ("AGM") of the members of the Company on Monday, September 29, 2025;
3. To close the register of members and share transfer books from September 23, 2025, to September 29, 2025 (both days inclusive) for the purpose of AGM. Accordingly, the cut-off date, to ascertain the eligibility of members for remote e-voting and polling/ e-voting at AGM, is September 22, 2025, i.e., the date prior to the commencement of book closure;
4. The re-appointment of Mr. Sanjiv Goyal (DIN- 00002841), director, who retire by rotation, in the forthcoming AGM.
5. The appointment of M/s. P. Chadha & Associates, Practicing Company Secretaries (Certificate of Practice no. 12409, Membership no. 32856 and Peer Review Certificate no. 1671/2022 valid upto January 31, 2027) as Secretarial Auditors of the Company for Audit period of for a period of Five (5) consecutive years commencing from the conclusion of 30th AGM till the conclusion of 35th AGM of the Company to be held in the year 2030 (i.e., to conduct the secretarial audit for financial year ("FY") 2025-26 to FY 2029-30), subject to approval of the members of the Company at the AGM;
6. The re-appointment of Mr. Vimal Kumar Aggarwal, proprietor of M/s V. Kumar &

Associates (Firm registration number: 100137), Practicing Cost Accountant as Cost Auditors for the FY 2025-26;

7. The adoption of new set of Articles of Association of the Company subject to approval of the members of the Company at the AGM.

The relevant disclosures regarding the appointment in Point No. 5 and 6 have been enclosed as per **Annexure- B**.

The Board Meeting commenced at 03:00 P.M. IST and concluded at 04:20 P.M. IST.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For **Nectar Lifesciences Limited**

(Sanjaymohan Singh Rawat)

Company Secretary & Compliance Officer

NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali), Punjab -140507, Tel. +91-1762-532 001, Fax +91-1762-531 833, Email : cs@neclife.com, Website : www.neclife.com, [CIN: L24232PB1995PLC016664]

Statement of Financial Results for the Quarter ended 30.06.2025 (Rs in Lacs)

S. No.	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25	30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25
		Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
I	Income from Operations								
	Sales	34,026.22	48,931.79	41,750.91	1,90,839.82	34,026.22	48,931.79	41,750.91	1,90,839.82
	Less: GST Recovered	5,959.71	6,041.03	5,866.21	23,842.46	5,959.71	6,041.03	5,866.21	23,842.46
	Revenue from Operations	28,066.51	42,890.76	35,884.70	1,66,997.36	28,066.51	42,890.76	35,884.70	1,66,997.36
	Other operating Income	0.63	178.70	45.27	310.07	0.63	178.70	45.27	310.07
II	Other Income	34.99	7.77	55.08	189.09	34.99	7.77	55.08	189.09
III	Total Income (I + II)	28,102.13	43,077.23	35,985.05	1,67,496.52	28,102.13	43,077.23	35,985.05	1,67,496.52
IV	Expenses								
	(a) Cost of Materials consumed	23,606.86	40,569.89	29,698.35	1,25,072.26	23,606.86	40,569.89	29,698.35	1,25,072.26
	(b) Purchase of Stock in Trade	-	-	-	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2,747.09	9,688.40	(5,964.12)	11,728.69	2,747.09	9,688.40	(5,964.12)	11,728.69
	(d) Employee benefits expense	2,426.35	2,380.70	2,398.66	9,647.46	2,426.35	2,380.70	2,398.66	9,647.46
	(e) Finance costs	1,869.52	1,767.20	1,997.68	7,457.83	1,869.52	1,767.20	1,997.68	7,457.83
	(f) Depreciation and amortisation expense	1,651.57	1,576.69	1,546.03	6,238.94	1,651.57	1,576.69	1,546.03	6,238.94
	(g) Other expenses	5,476.17	5,860.85	5,816.74	23,504.74	5,476.17	5,860.85	5,816.74	23,504.74
	Total Expenses (IV)	37,777.56	61,843.73	35,493.34	1,83,649.92	37,777.56	61,843.73	35,493.34	1,83,649.92
V	Profit before exceptional items and tax (III- IV)	(9,675.43)	(18,766.50)	491.71	(16,153.40)	(9,675.43)	(18,766.50)	491.71	(16,153.40)
VI	Exceptional Items	-	-	-	-	-	-	-	-
VII	Profit from ordinary activities before tax (V - VI)	(9,675.43)	(18,766.50)	491.71	(16,153.40)	(9,675.43)	(18,766.50)	491.71	(16,153.40)
VIII	Tax Expense								
	Current Tax	-	-	-	-	-	-	-	-
	Deferred Tax	(3,352.35)	(5,757.58)	194.80	(4,785.32)	(3,352.35)	(5,757.58)	194.80	(4,785.32)
IX	Profit for the period from continuing operations (VII-VIII)	(6,323.08)	(13,008.92)	296.91	(11,368.08)	(6,323.08)	(13,008.92)	296.91	(11,368.08)
	Other Comprehensive Income								
	Items that will not be reclassified subsequently to profit or loss								
	Remeasurement of the net defined benefit liability/asset (Net of Tax)	-	53.98	-	53.98	-	53.98	-	53.98
	Items that will be reclassified subsequently to profit or loss								
	Foreign Exchange Translation Reserve (Net of Tax)	-	-	-	-	0.01	-	-	-
	Total Other Comprehensive Income, (Net of Tax)	-	53.98	-	53.98	0.01	53.98	-	53.98
	Total Comprehensive Income for the period	(6,323.08)	(12,954.94)	296.91	(11,314.10)	(6,323.07)	(12,954.94)	296.91	(11,314.10)
X	Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up)								
	a) Basic (In Rs.) - After Exceptional Item	(2.82)	(5.80)	0.13	(5.07)	(2.82)	(5.80)	0.13	(5.07)
	b) Basic (In Rs.) - Before Exceptional Item	(2.82)	(5.80)	0.13	(5.07)	(2.82)	(5.80)	0.13	(5.07)
	c) Diluted (In Rs.) - After Exceptional Item	(2.82)	(5.80)	0.13	(5.07)	(2.82)	(5.80)	0.13	(5.07)
	d) Diluted (In Rs.) - Before Exceptional Item	(2.82)	(5.80)	0.13	(5.07)	(2.82)	(5.80)	0.13	(5.07)

Notes

- 1 The above financial results were reviewed by Audit Committee on August 14, 2025 and approved by the Board in its meeting held on August 14, 2025. The statutory auditors of the Company have conducted a "Limited Review" of the above standalone and consolidated unaudited financial results for the quarter ended on June 30, 2025.
- 2 The company is exclusively in the pharmaceutical business segment.
- 3 Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- 4 The figures of the last quarter for the previous financial year i.e. March 31, 2025 are the balancing figures between the audited figure in respect of the full previous financial year ended March 31, 2025 and the unaudited published year to date figures upto the third quarter ended December 31, 2024 which was subject to limited review and not audit.
- 5 The Company has undertaken following transactions after the end of the quarter:
 - i. Sale of business of manufacture, distribution, marketing and sale of active pharmaceutical ingredients and formulations ("Business") of the Company to Ceph Lifesciences Private Limited ("Purchaser") for INR 12,70,00,00,000/- (Indian Rupees one thousand two hundred seventy crore only) subject to adjustments in accordance with the terms of the business transfer agreement , as a slump sale on a going concern basis; and
 - ii. Sale, transfer and delivery of the assets of the Company in relation to its menthol business ("Assets") to Purchaser for INR 20,00,00,000/- (Indian Rupees Twenty Crores only), plus applicable GST payable on the sale of such Assets under the applicable law.

Dated: 14.08.2025

Place: Chandigarh

**By Order of the Board of Directors
of Nectar Lifesciences Limited**

**(Sanjiv Goyal)
Chairman & Managing Director**



Independent Auditor's review report on the Quarterly Unaudited Standalone Financial Results of the company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors of,
Nectar Lifesciences Limited,
Village Saidpura, Tehsil Derabassi,
Distt. S.A.S. Nagar (Mohali) Punjab

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Nectar Lifesciences Limited ("the Company") for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to



inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Deepak Jindal & Co.
Chartered Accountants

Firm Regn. No. 023023N



M. No. 514746

Date: 14th Aug 2025

Place: Chandigarh

UDIN: 25514746BMIPUD8916



Independent Auditors' review report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended

To
The Board of Directors
Nectar Lifesciences Limited
Village Saidpura, Tehsil Derabassi,
Distt. S.A.S. Nagar (Mohali) Punjab

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Nectar Lifesciences Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended June 30, 2025 ("the Statement"), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been compiled from the related consolidated financial statements and been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and the relevant requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial & accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not




enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the subsidiaries listed as below: -
 - a. NECLIFE PT, UNIPESSOAL LDA (Inoperative)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, as amended, including the matter in which it is to be disclosed, or that it contains any material misstatement.
6. The unaudited consolidated financial results include the unaudited interim financial information of the subsidiary which have not been reviewed by their auditors, whose interim financial information excluding consolidation eliminations reflects total revenue of Nil, total net profit/ (loss) after tax of Nil, total comprehensive income/ (loss) of Nil for the quarter ended June 30, 2025, as considered in the Statement. The unaudited financial information has been approved and furnished to us by the management. Our conclusion in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited financial information. According to the information and explanations given to us by management, this interim financial information's are not material to the Group.

Our conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the management.

Date: 14th Aug 2025
Place: Chandigarh

For Deepak Jindal & Co.
Chartered Accountants
Firm Regn. No. DD003023N

(Onkar Singh)
Partner
M. No. 514746

UDIN: 25514746BM1PUE7873

Annexure-B

Details as required as per LODR Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, as amended, are as follows:

Sr. No.	Particulars	Disclosures	
		M/s. P. Chadha & Associates	M/s V. Kumar & Associates
1.	Reason for change viz. Appointment, re-appointment, resignation, removal, death or otherwise	Appointment of M/s. P. Chadha & Associates, Peer Reviewed Firm of Company Secretaries in Practice, as Secretarial Auditors of the Company.	Re-Appointment of M/s V. Kumar & Associates, Firm of Cost Accountants in Practice, as Cost Auditors of the Company.
2.	Date of appointment/ re-appointment/ cessation (as applicable) & term of appointment/re-appointment	The Board at its meeting held on August 14, 2025, approved the appointment of M/s. P. Chadha & Associates, Practising Company Secretaries as Secretarial Auditors of the Company for Audit period of Five (5) consecutive years for FY 2025-26 to FY 2029-30.	The Board at its meeting held on August 14, 2025, approved the re-appointment of M/s V. Kumar & Associates, Practising Cost Accountants as Cost Auditors of the Company for FY 2025-26.
3.	Brief profile (in case of appointment)	Mr. Prince Chadha, proprietor of M/s. P. Chadha & Associates, Practising Company Secretary, has vast experience in both the private and public sectors and has conducted secretarial audit of Venus Remedies Limited, Beckons Industries Limited, Best Foods Limited, Ajooni Biotech Limited etc.	Mr. Vimal Kumar Aggarwal, proprietor of M/s V. Kumar & Associates, Practising Cost Accountants and Certified Management Accountant (USA) has vast experience in Audits of Cost, Excise, Service Tax, Internal & Operational Stock, Inventory Valuation and Verification, Pricing, Cost Reduction, Product & Customer Profitability Analysis, MIS & System Designing, Investment and Banking Services (Including Loan Syndication).
4.	Disclosure of relationships between directors (in case of appointment of a director)	He does not have any relationship with any other director of the Company.	He does not have any relationship with any other director of the Company.